223 related articles for article (PubMed ID: 24265828)
1. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys.
Mao CP; Brovarney MR; Dabbagh K; Birnböck HF; Richter WF; Del Nagro CJ
PLoS One; 2013; 8(11):e80533. PubMed ID: 24265828
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix.
Vugmeyster Y; Howell K; Bakshl A; Flores C; Canova-Davis E
Cytometry A; 2003 Apr; 52(2):101-9. PubMed ID: 12655653
[TBL] [Abstract][Full Text] [Related]
3. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys.
Vugmeyster Y; Howell K; McKeever K; Combs D; Canova-Davis E
Int Immunopharmacol; 2003 Oct; 3(10-11):1477-81. PubMed ID: 12946444
[TBL] [Abstract][Full Text] [Related]
4. Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.
Nickerson-Nutter C; Tchistiakova L; Seth NP; Kasaian M; Sibley B; Olland S; Zollner R; Brady WA; Mohler KM; Baum P; Wahl A; Herber D; Vugmeyster Y; Wensel D; Wolfman NM; Gill D; Collins M; Dunussi-Joannopoulos K
Rheumatology (Oxford); 2011 Jun; 50(6):1033-44. PubMed ID: 21258049
[TBL] [Abstract][Full Text] [Related]
5. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).
Ryan AM; Sokolowski SA; Ng CK; Shirai N; Collinge M; Shen AC; Arrington J; Radi Z; Cummings TR; Ploch SA; Stephenson SA; Tripathi NK; Hurst SI; Finch GL; Leach MW
Toxicol Pathol; 2014 Oct; 42(7):1069-81. PubMed ID: 24604381
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.
Davies A; Berge C; Boehnke A; Dadabhoy A; Lugtenburg P; Rule S; Rummel M; McIntyre C; Smith R; Badoux X
Adv Ther; 2017 Oct; 34(10):2210-2231. PubMed ID: 28983819
[TBL] [Abstract][Full Text] [Related]
7. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.
Vugmeyster Y; Beyer J; Howell K; Combs D; Fielder P; Yang J; Qureshi F; Sandlund B; Kawaguchi L; Dummer W; Lowman H; McKeever K
J Immunother; 2005; 28(3):212-9. PubMed ID: 15838377
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
9. Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey.
Chen J; Su C; Lu Q; Shi W; Zhang Q; Wang X; Long J; Yang Q; Li L; Jia X; Wang J; Da W; Liu X; Wu M; Qian Q
Mol Cancer Ther; 2008 Jun; 7(6):1562-8. PubMed ID: 18524844
[TBL] [Abstract][Full Text] [Related]
10. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
11. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
[TBL] [Abstract][Full Text] [Related]
12. Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.
Theil D; Smith P; Huck C; Gilbart Y; Kakarieka A; Leppert D; Rauld C; Schmid C; Baumgartner R; Stuber N; Cordoba F; Dubost V; Darribat K; Jivkov M; Frieauff W; Kneuer R; Stoeckli M; Reinker S; Mansfield K; Carballido JM; Couttet P; Weckbecker G
Front Immunol; 2019; 10():1340. PubMed ID: 31281311
[TBL] [Abstract][Full Text] [Related]
13. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab.
Bittner B; Richter WF; Hourcade-Potelleret F; Herting F; Schmidt J
Drug Res (Stuttg); 2014 Nov; 64(11):569-75. PubMed ID: 24452524
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
[TBL] [Abstract][Full Text] [Related]
15. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.
Kelishadi SS; Azimzadeh AM; Zhang T; Stoddard T; Welty E; Avon C; Higuchi M; Laaris A; Cheng XF; McMahon C; Pierson RN
J Clin Invest; 2010 Apr; 120(4):1275-84. PubMed ID: 20335656
[TBL] [Abstract][Full Text] [Related]
16. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A; Avivi I; Bittner B; Bouabdallah R; Brewster M; Catalani O; Follows G; Haynes A; Hourcade-Potelleret F; Janikova A; Larouche JF; McIntyre C; Pedersen M; Pereira J; Sayyed P; Shpilberg O; Tumyan G
J Clin Oncol; 2014 Jun; 32(17):1782-91. PubMed ID: 24821885
[TBL] [Abstract][Full Text] [Related]
17. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
[TBL] [Abstract][Full Text] [Related]
19. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
Aue G; Lindorfer MA; Beum PV; Pawluczkowycz AW; Vire B; Hughes T; Taylor RP; Wiestner A
Haematologica; 2010 Feb; 95(2):329-32. PubMed ID: 19679883
[TBL] [Abstract][Full Text] [Related]
20. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
